| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.096 | 0.04 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.089 | 0.04 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.081 | 0.09 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.084 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.078 | 0.1 |